Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | RCE1 | Q9Y256 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30272856 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KDM4ERAB9AGLAHPGD | |
| SCHEMBL329214 | 0.84 | ALDH1A1 (0.53) | ALDH1A1KDM4ERAB9AGLAHPGD | |
| SCHEMBL164735 | 0.83 | CA2 (0.59) | ALDH1A1KDM4ERAB9AGLAHPGD | |
| SCHEMBL1051623 | 0.83 | ALDH1A1 (0.51) | ALDH1A1KDM4ERAB9AGLAHPGD | |
| SCHEMBL642753 | 0.81 | CA2 (0.58) | ALDH1A1KDM4ERAB9AGLAHPGD | |
| Acridine SCHEMBL28003717 | 0.81 | CA2 (0.58) | ALDH1A1KDM4ERAB9AGLAHPGD | |
| Methane SCHEMBL28725834 | 0.81 | CA2 (0.58) | ALDH1A1KDM4ERAB9AGLAHPGD | |
| SCHEMBL686665 | 0.81 | TTR (0.55) | ALDH1A1KDM4EKMT2APOLBGAA | |
| SCHEMBL920170 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KDM4ERAB9AGLAHPGD | |
| SCHEMBL29843410 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KDM4ERAB9AGLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9292710-A | — | — | None | — | — | JP | disclosed |
| EP-4366733-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230357744-A1 | ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4225315-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES | Nimmune Biopharma, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230192652-A1 | PLXDC2 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4196475-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230167083-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230128450-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| EP-1916245-A1 | INDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-1911759-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-7297555-B2 | Hydrophilic chemiluminescent acridinium labeling reagents | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2007-11-20 | — | — | US | disclosed |
| US-20050255528-A1 | Hydrophilic chemiluminescent acridinium labeling reagents | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2005-11-17 | — | — | US | disclosed |
| EP-1539702-A4 | HYDROPHILIC CHEMILUMINESCENT ACRIDINIUM LABELING REAGENTS | QUEST DIAGNOSTICS INVEST INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6924154-B2 | Hydrophilic chemilumescent acridinium labeling reagents | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1539702-A2 | HYDROPHILIC CHEMILUMINESCENT ACRIDINIUM LABELING REAGENTS | Quest Diagnostics Investments Incorporated (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018418-A2 | HYDROPHILIC CHEMILUMINESCENT ACRIDINIUM LABELING REAGENTS | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040038294-A1 | Comprises hydrophilic sulfoalkyl substituents/linkers which offset hydrophobicity of acridinium ring system; improved attachment with antibody/handling | QUEST DIAGNOSTIC INVESTMENTS INCORPORATED | 2004-02-26 | — | — | US | disclosed |
| JP-H09292710-A | WATER-SOLUBLE PHOTOSENSITIVE COMPOSITION AND PRODUCTION OF COLOR CATHODE RAY TUBE USING THAT | HITACHI LTD | 1997-11-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128450-A1 | NLRX1 LIGANDS | NLRP3, NLRP1, NOD1 | ALDH1A1 4043/4885KDM4E 4410/4885RAB9A 1425/4885 |
| US-20230167083-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | ALDH1A1 4156/4885KDM4E 3554/4885RAB9A 3013/4885 |
| US-20230192652-A1 | PLXDC2 LIGANDS | PLP2, PDCD1LG2, LCP2 | ALDH1A1 3872/4885KDM4E 3914/4885RAB9A 2749/4885 |
| US-20050255528-A1 | Hydrophilic chemiluminescent acridinium labeling reagents | CTH, CBS, AHCY | ALDH1A1 1709/4885KDM4E 4666/4885RAB9A 4306/4885 |
| US-20040038294-A1 | Comprises hydrophilic sulfoalkyl substituents/linkers which offset hydrophobicity of acridinium ring system; improved attachment with antibody/handling | CTH, CBS, TST | ALDH1A1 2567/4885KDM4E 4312/4885RAB9A 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.